Iodine-131 Combined With Plasma Exchange Treatment in Graves' Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20
- PMID: 39996246
- PMCID: PMC11849068
- DOI: 10.1016/j.gastha.2024.100600
Iodine-131 Combined With Plasma Exchange Treatment in Graves' Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20
Abstract
Background and aims: The purpose of this retrospective study is to describe the Graves' hyperthyroidism patients with severe liver injury treated by iodine-131 combined with plasma exchange (PE).
Methods: The patients who had hyperthyroidism caused by Graves' disease, with severe liver injury (The level of total bilirubin ≥12 mg/dL), and after 1 week of liver protective medication treatment, the patient's liver function did not improve, were enrolled in this study. All patients were treated with iodine-131 and PE. The patients' laboratory data after 3 months of isotope therapy were collected.
Results: In this study, there were 8 patients included, the average model for end-stage liver disease (MELD) scores were greater than 20 (ranges from 19 to 30) at baseline. The levels of hemoglobin, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, glutamyl transpeptidase, MELD scores, free triiodothyronine, free thyroxine, antithyroid peroxidase autoantibody and serum thyrotropin receptor antibodies after PE treatment were significantly lower than before PE treatment (P < .05). The level of total bilirubin at 3 months post-131I treatment was significantly lower than pre-131I treatment (P = .0200), the same was the level of direct bilirubin (P = .0200).
Conclusion: Our study enrolled Graves' hyperthyroidism patients with severe liver injury whose average MELD scores were greater than 20, and shows that liver function test can recover on about 3 months treated iodine-131 combined with PE therapy.
Keywords: Graves’ Disease; Isotope I131 Therapy; Liver Failure; Plasma Exchange.
© 2024 The Authors.
Figures



Similar articles
-
The Effect of Long-Term Inorganic Iodine on Intrathyroidal Iodothyronine Content and Gene Expression in Mice with Graves' Hyperthyroidism.Thyroid. 2023 Mar;33(3):330-337. doi: 10.1089/thy.2022.0496. Epub 2023 Feb 1. Thyroid. 2023. PMID: 36565031 Free PMC article.
-
Combined Age with Mean Decrease Rates of Total Bilirubin and MELD Score as a Novel and Simple Clinical Predictor on 90-Day Transplant-Free Mortality in Adult Patients with Acute Liver Failure Undergoing Plasma Exchange: A Single-Center Retrospective Study.Can J Gastroenterol Hepatol. 2023 Nov 7;2023:6115499. doi: 10.1155/2023/6115499. eCollection 2023. Can J Gastroenterol Hepatol. 2023. PMID: 38021269 Free PMC article.
-
Serum immunoglobulin G4 levels and Graves' disease phenotype.Endocrine. 2017 Feb;55(2):478-484. doi: 10.1007/s12020-016-1157-5. Epub 2016 Nov 7. Endocrine. 2017. PMID: 27819113
-
Graves' disease in children.Ann Endocrinol (Paris). 2018 Dec;79(6):647-655. doi: 10.1016/j.ando.2018.08.001. Epub 2018 Aug 16. Ann Endocrinol (Paris). 2018. PMID: 30180972 Review.
-
Graves' Disease: Can It Be Cured?Endocrinol Metab (Seoul). 2019 Mar;34(1):29-38. doi: 10.3803/EnM.2019.34.1.29. Endocrinol Metab (Seoul). 2019. PMID: 30912336 Free PMC article. Review.
References
-
- Ross D.S., Burch H.B., Cooper D.S., et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–1421. - PubMed
-
- Connelly-Smith L., Alquist C.R., Aqui N.A., et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38:77–278. - PubMed
LinkOut - more resources
Full Text Sources